Integer Holdings Corp adjusts medical portfolio, shares track sector peers

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 19:34.

Integer Holdings Corp (US45826J1051) continues to operate as a key contract manufacturer for medical device and cardiovascular companies, with its shares listed on the NYSE next to sector peers such as Medtronic and Boston Scientific. The company maintains a diversified portfolio across cardiac rhythm management, neuromodulation and vascular products, according to recent investor materials and third-party coverage.

How Integer positions itself

Integer Holdings Corp presents itself as a leading medical device outsource manufacturer, supplying proprietary components and finished devices to major healthcare OEMs across the United States, Europe and Asia. Its investor relations site describes core capabilities in design, development and manufacturing for cardiac, neuromodulation and vascular therapies. Integer investor presentation

The company emphasizes long-term contracts and deep engineering partnerships with leading device makers, focusing on complex components such as implantable leads, stimulation electrodes and vascular delivery systems. Industry commentary notes that outsourcing in medical technology has grown steadily as OEMs seek cost efficiency and specialized manufacturing expertise. Reuters analysis on medtech outsourcing

Weekday focus on operations

Operations at Integer span multiple manufacturing sites in North America, Europe and Asia, with facilities dedicated to precision machining, molding, assembly and sterilization of medical products. The company reports ongoing investments in automation and quality systems to meet stringent regulatory requirements from bodies such as the FDA and European authorities. Integer annual report

Integer’s strategy centers on deepening relationships with large OEM clients while expanding into adjacent categories like neuromodulation and structural heart, according to analyst commentary tracking the medtech contract manufacturing space. Coverage from sell-side research highlights solid demand for minimally invasive devices and implantable technologies, which supports long-term volume for component suppliers. Morgan Stanley medtech outsourcing note

The product behind the stock

One representative product line for Integer Holdings Corp is its implantable cardiac leads, which are used in devices such as pacemakers and cardioverter defibrillators produced by major OEMs. These leads must maintain long-term reliability inside the body, requiring advanced materials, insulation systems and precision manufacturing.

Where the stock trades today

Integer Holdings Corp shares trade on the NYSE in US dollars; a current, verified price was not available at the time of writing, but the listing remains active on the exchange.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.